CEO Pardeep Nijhawan purchased 20,571 shares at $1.58, marking the largest insider purchase in the company's history. This significant buy by top management suggests confidence in the stock's recent surge and potential for further upside.
Price context
The stock has rallied 153.62% over the past five days and 94.87% over the last month, though it remains 22.75% below its 52-week high of $2.95.
Catalysts to watch
- •Reaffirmed 2026 clinical study timeline for EB06 (April 20)
- •Market cap milestone of US$68m (April 23)
Risks
The stock carries high volatility risk with a beta of 1.278 and significant short interest representing 6.28% of the float.
AI-generated context from public data. Not investment advice. Verify before trading.